21:22 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Ph IIb hold

Arrowhead said FDA placed a clinical hold on the double-blind, placebo-controlled, U.S. Phase IIb Heparc-2004 trial of IV ARC-520. Arrowhead said FDA placed the hold after deaths occurred in a non-human primate toxicology study in...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

ARC-520: Phase IIb started

Arrowhead began the open-label, Australian and New Zealand Phase IIb MONARCH (Heparc-2008) trial to evaluate 2 mg/kg IV ARC-520 every 4 weeks for 48 weeks alone or with entecavir and Pegasys peginterferon alfa-2a in up...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Completed Phase II enrollment

Cerulean completed enrollment of 110 patients in an open-label, international Phase II trial comparing 15 mg/m 2 IV CRLX101 plus IV Avastin on days 1 and 15 of a 28-day cycle vs. standard of care...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Phase Ib started

Cerulean began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate weekly IV CRLX101 alone or with IV Avastin bevacizumab in up to 36 patients. Cerulean has exclusive, worldwide rights to develop and commercialize CRLX101...
07:00 , Oct 12, 2015 |  BioCentury  |  Regulation

Learning in liver

Jennifer Rhodes, Staff Writer   Patients and caregivers at FDA's patient-focused drug development meeting on alpha-1 antitrypsin deficiency are desperate for treatments for liver-affected patients, whose only option is a transplant. With two RNAi programs...
07:00 , Oct 1, 2015 |  BC Innovations  |  Product R&D

Escaping the liver

Having addressed one of the two big problems of RNAi delivery - getting therapeutic levels of the molecules inside cells - Arrowhead Research Corp. now believes it has solved the second, with a modification to...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

ARC-520: Additional Phase IIa data

Top-line data from 6 treatment-naive hepatitis B e antigen (HBeAg)-positive patients with active chronic HBV infection in an open-label cohort of the double-blind, placebo-controlled, dose-escalation, Hong Kong Phase IIa Heparc-2001 trial showed that a single...
00:10 , Sep 25, 2015 |  BC Extra  |  Clinical News

Arrowhead rises on new Phase IIa HBV data

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.45 to $7.19 after it said ARC-520 reduced circulating hepatitis B surface antigen (HBsAg) levels by a maximum of 99% in treatment-naive patients with HBV infection in a Phase IIa...
00:57 , Sep 12, 2015 |  BC Extra  |  Clinical News

Arrowhead chooses RNAi candidate for ccRCC

Arrowhead Research Corp. (NASDAQ:ARWR) gained $0.68 (12%) to $6.40 on Friday after it selected ARC-HIF2 as its first development candidate using the company's dynamic polyconjugate (DPC) platform for RNAi delivery to tissues outside the liver....
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

CRLX101: Phase Ib started

Cerulean began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV CRLX101 on days 1 and 15 of a 28-day cycle plus weekly IV paclitaxel in up to 18 patients. Cerulean has exclusive, worldwide...